Erectile dysfunction in diabetes mellitus

Journal of Sexual Medicine

Volumn 6, Issue 5, 2009, Pages 1232-1247

  Malavige, Lasantha S ^a,b,c   Levy, Jonathan C ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SRI JAYEWARDENEPURA   (Sri Lanka)

Author keywords

Diabetes; Erectile dysfunction; Hypogonadism; Pathophysilogy; PDE5 inhibitors; Testosterone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LOSARTAN; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TESTOSTERONE; THIAZIDE DIURETIC AGENT; VALSARTAN; VARDENAFIL;

AGE; BALANITIS; CALORIC RESTRICTION; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GENITAL PAIN; GLYCEMIC CONTROL; GYNECOMASTIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGONADISM; HYPOTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LIBIDO DISORDER; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PENILE FIBROSIS; PENIS PROSTHESIS; PEYRONIE DISEASE; PHIMOSIS; POLYCYTHEMIA; PREMATURE EJACULATION; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; SEXUAL COUNSELING; SIDE EFFECT; SLEEP APNEA SYNDROME; SMOKING; SOCIAL INTERACTION; SUBFERTILITY; SYNCOPE; THERAPY RESISTANCE;

EID: 65149086938     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.01168.x     Document Type: Review

References (133)

1. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia 1980;18:279-83.
2. De Berardis G, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Pellegrini F, Sacco M, Tognoni G, Valentini M, Nicolucci A. Erectile dysfunction and quality of life in type 2 diabetic patients: A serious problem too often overlooked. Diabetes Care 2002;25:284-91.
3. Fedele D, Coscelli C, Santeusanio F, Bortolotti A, Chatenoud L, Colli E, Landoni M, Parazzini F. Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care 1998;21:1973-7.
4. Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002;25:1458-63.
5. Siu SC, Lo SK, Wong KW, Ip KM, Wong YS. Prevalence of and risk factors for erectile dysfunction in Hong Kong diabetic patients. Diabet Med 2001;18:732-8.
6. Cho NH, Ahn CW, Park JY, Ahn TY, Lee HW, Park TS, Kim IJ, Pomerantz K, Park C, Kimm KC, Choi DS. Prevalence of erectile dysfunction in Korean men with Type 2 diabetes mellitus. Diabet Med 2006;23:198-203.
7. Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS. Prevalence of erectile dysfunction among 7,689 patients with diabetes or hypertension, or both. Urology 2004;64:1196-201.
8. Malavige LS, Jayaratne SD, Kathriarachchi ST, Sivayogan S, Fernando DJ, Levy JC. Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. J Sex Med 2008;5:2125-34.
9. El-Sakka AI, Tayeb KA. Erectile dysfunction risk factors in noninsulin dependent diabetic Saudi patients. J Urol 2003;169:1043-7.
10. Sasaki H, Yamasaki H, Ogawa K, Nanjo K, Kawamori R, Iwamoto Y, Katayama S, Shirai M. Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Res Clin Pract 2005;70:81-9.
11. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
12. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts male aging study. J Urol 2000;163:460-3.
13. Penson DF, Latini DM, Lubeck DP, Wallace KL, Henning JM, Lue TF. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 2003;26:1093-9.
14. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-404.
15. Deutsch S, Sherman L. Previously unrecognized diabetes mellitus in sexually impotent men. JAMA 1980;244:2430-2.
16. Lewis RW. Epidemiology of erectile dysfunction. Urol Clin North Am 2001;28:209-16, vii.
17. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
18. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: The evolving epidemic: The international diabetes federation consensus workshop. Diabetes Care 2004;27:1798-811.
19. Oldroyd J, Banerjee M, Heald A, Cruickshank K. Diabetes and ethnic minorities. Postgrad Med J 2005;81:486-90.
20. DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003;26:61-9.
21. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world - a growing challenge. N Engl J Med 2007;356:213-5.
22. Sasaki K, Yoshimura N, Chancellor MB. Implications of diabetes mellitus in urology. Urol Clin North Am 2003;30:1-12.
23. Cho BL, Kim YS, Choi YS, Hong MH, Seo HG, Lee SY, Shin HC, Kim CH, Moon YS, Cha HS, Kim BS. Prevalence and risk factors for erectile dysfunction in primary care: Results of a Korean study. Int J Impot Res 2003;15:323-8.
24. NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 1993;270:83-90.
25. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
26. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319-26.
27. Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): A state-of-the-science review. Int J Impot Res 2002;14:226-44.
28. Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. J Urol 1998;159:1988-92.
29. Kalter-Leibovici O, Wainstein J, Ziv A, Harman-Bohem I, Murad H, Raz I. Clinical, socioeconomic, and lifestyle parameters associated with erectile dysfunction among diabetic men. Diabetes Care 2005;28:1739-44.
30. Fedele D, Bortolotti A, Coscelli C, Santeusanio F, Chatenoud L, Colli E, Lavezzari M, Landoni M, Parazzini F. Erectile dysfunction in type 1 and type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int J Epidemiol 2000;29:524-31.
31. McCulloch DK, Young RJ, Prescott RJ, Campbell IW, Clarke BF. The natural history of impotence in diabetic men. Diabetologia 1984;26:437-40.
32. Klein R, Klein BE, Lee KE, Moss SE, Cruickshanks KJ. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 1996;19:135-41.
33. Zheng H, Bidasee KR, Mayhan WG, Patel KP. Lack of central nitric oxide triggers erectile dysfunction in diabetes. Am J Physiol Regul Integr Comp Physiol 2007;292:R1158-64.
34. Zheng H, Fan W, Li G, Tam T. Predictors for erectile dysfunction among diabetics. Diabetes Res Clin Pract 2006;71:313-9.
35. Roth A, Kalter-Leibovici O, Kerbis Y, Tenenbaum-Koren E, Chen J, Sobol T, Raz I. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: A community survey among 1,412 Israeli men. Clin Cardiol 2003;26:25-30.
36. Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: Association with glycemic control. J Urol 2000;163:788-91.
37. Matfin G, Jawa A, Fonseca VA. Erectile dysfunction: Interrelationship with the metabolic syndrome. Curr Diab Rep 2005;5:64-9.
38. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: Can lifestyle changes modify risk? Urology 2000;56:302-6.
39. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Rossi MC, Sacco M, Tognoni G, Valentini M, Nicolucci A. Identifying patients with type 2 diabetes with a higher likelihood of erectile dysfunction: The role of the interaction between clinical and psychological factors. J Urol 2003;169:1422-8.
40. Heruti RJ, Uri I, Arbel Y, Swartzon M, Galor S, Justo D. Erectile dysfunction severity might be associated with poor cardiovascular prognosis in diabetic men. J Sex Med 2007;4:465-71.
41. Shabsigh R, Shah M, Sand M. Erectile dysfunction and men's health: Developing a comorbidity risk calculator. J Sex Med 2008;5:1237-43.
42. Chew KK, Bremner A, Jamrozik K, Earle C, Stuckey B. Male erectile dysfunction and cardiovascular disease: Is there an intimate nexus? J Sex Med 2008;5:928-34.
43. Rosen RC, Kostis JB, Jekelis AW. Beta-blocker effects on sexual function in normal males. Arch Sex Behav 1988;17:241-55.
44. Rosen RC. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl 1997;1:47-51.
45. Bortolotti A, Fedele D, Chatenoud L, Colli E, Coscelli C, Landoni M, Lavezzari M, Santeusanio F, Parazzini F. Cigarette smoking: A risk factor for erectile dysfunction in diabetics. Eur Urol 2001;40:392-6. Discussion 97.
46. Nicolosi A, Moreira ED Jr, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: Cross-national study of the prevalence and correlates of erectile dysfunction. Urology 2003;61:201-6.
47. Ahn TY, Park JK, Lee SW, Hong JH, Park NC, Kim JJ, Park K, Park H, Hyun JS. Prevalence and risk factors for erectile dysfunction in Korean men: Results of an epidemiological study. J Sex Med 2007;4:1269-76.
48. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: A meta-analysis. Diabetes Care 2001;24:1069-78.
49. Khoo EM, Tan HM, Low WY. Erectile dysfunction and comorbidities in aging men: An urban cross-sectional study in Malaysia. J Sex Med 2008;5:2925-34.
50. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Rossi MC, Sacco M, Tognoni G, Valentini M, Nicolucci A. Clinical and psychological predictors of incidence of self-reported erectile dysfunction in patients with type 2 diabetes. J Urol 2007;177:252-7.
51. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Rossi MC, Sacco M, Tognoni G, Valentini M, Nicolucci A. Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. Diabetes Care 2005;28:2637-43.
52. Bancroft J, Gutierrez P. Erectile dysfunction in men with and without diabetes mellitus: A comparative study. Diabet Med 1996;13:84-9.
53. Bancroft J, Janssen E. The dual control model of male sexual response: A theoretical approach to centrally mediated erectile dysfunction. Neurosci Biobehav Rev 2000;24:571-9.
54. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Briganti A, Salonia A, Rigatti P, Montorsi F. The artery size hypothesis: A macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 2005;96:19M-23M.
55. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:771-6.
56. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-10.
57. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999;48:1856-62.
58. Aoki R, Ikarugi H, Naemura A, Ijiri Y, Yamashita T, Yamamoto J. Endothelial dysfunction precedes atherosclerotic lesions and platelet activation in high fat diet-induced prothrombotic state. Thromb Res 2006;117:529-35.
59. Miner M, Billups KL. Erectile dysfunction and dyslipidemia: Relevance and role of phosphodiesterase type-5 inhibitors and statins. J Sex Med 2008;5:1066-78.
60. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M. Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003;112:1049-57.
61. Esposito K, Ciotola M, Giugliano F, Sardelli L, Maiorino MI, Beneduce F, De Sio M, Giugliano D. Phenotypic assessment of endothelial microparticles in diabetic and nondiabetic men with erectile dysfunction. J Sex Med 2008;5:1436-42.
62. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006;116:1071-80.
63. Yang CC, Bradley WE. Innervation of the human glans penis. J Urol 1999;161:97-102.
64. Nehra A, Moreland RB. Neurologic erectile dysfunction. Urol Clin North Am 2001;28:289-308.
65. Hecht MJ, Neundorfer B, Kiesewetter F, Hilz MJ. Neuropathy is a major contributing factor to diabetic erectile dysfunction. Neurol Res 2001;23:651-4.
66. Pegge NC, Twomey AM, Vaughton K, Gravenor MB, Ramsey MW, Price DE. The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. Diabet Med 2006;23:873-8.
67. Bleustein CB, Arezzo JC, Eckholdt H, Melman A. The neuropathy of erectile dysfunction. Int J Impot Res 2002;14:433-9.
68. Sima AA, Sugimoto K. Experimental diabetic neuropathy: An update. Diabetologia 1999;42:773-88.
69. Yagihashi S, Yamagishi S, Wada R. Pathology and pathogenetic mechanisms of diabetic neuropathy: Correlation with clinical signs and symptoms. Diabetes Res Clin Pract 2007;77(1 suppl):S184-9.
70. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001;24:1225-8.
71. Corona G, Mannucci E, Mansani R, Petrone L, Bartolini M, Giommi R, Forti G, Maggi M. Organic, relational and psychological factors in erectile dysfunction in men with diabetes mellitus. Eur Urol 2004;46:222-8.
72. Corrales JJ, Burgo RM, Garca-Berrocal B, Almeida M, Alberca I, Gonzalez-Buitrago JM, Orfao A, Miralles JM. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004;53:666-72.
73. Corona G, Mannucci E, Petrone L, Balercia G, Paggi F, Fisher AD, Lotti F, Chiarini V, Fedele D, Forti G, Maggi M. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007;4:1038-45.
74. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911-7.
75. Mikhail N. Does testosterone have a role in erectile function? Am J Med 2006;119:373-82.
76. Shabsigh R, Rajfer J, Aversa A, Traish AM, Yassin A, Kalinchenko SY, Buvat J. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006;60:1087-92.
77. Baba K, Yajima M, Carrier S, Akkus E, Reman J, Nunes L, Lue TF, Iwamoto T. Effect of testosterone on the number of NADPH diaphorase-stained nerve fibers in the rat corpus cavernosum and dorsal nerve. Urology 2000;56:533-8.
78. Hartmut Porst JB, ed. Standard practice in sexual medicine. 1st edition. Oxford: Blackwell; 2007.
79. Hatzichristou D, Hatzimouratidis K, Bekas M, Apostolidis A, Tzortzis V, Yannakoyorgos K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol 2002;168:615-20.
80. Spark RF, White RA, Connolly PB. Impotence is not always psychogenic. Newer insights into hypothalamic-pituitary-gonadal dysfunction. JAMA 1980;243:750-5.
81. Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994;17:405-11.
82. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89:5462-8.
83. Cohen PG. The hypogonadal-obesity cycle: Role of aromatase in modulating the testosterone-estradiol shunt-a major factor in the genesis of morbid obesity. Med Hypotheses 1999;52:49-51.
84. Marin P, Oden B, Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: Effects of androgens. J Clin Endocrinol Metab 1995;80:239-43.
85. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005;63:239-50.
86. Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction. Int J Impot Res 2007;19:213-7.
87. El-Sakka AI, Tayeb KA. Peyronie's disease in diabetic patients being screened for erectile dysfunction. J Urol 2005;174:1026-30.
88. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: Results of a large survey. BJU Int 2001;88:727-30.
89. Tefekli A, Kandirali E, Erol B, Tunc M, Kadioglu A. Peyronie's disease: A silent consequence of diabetes mellitus. Asian J Androl 2006;8:75-9.
90. Kadioglu A, Oktar T, Kandirali E, Kendirci M, Sanli O, Ozsoy C. Incidentally diagnosed Peyronie's disease in men presenting with erectile dysfunction. Int J Impot Res 2004;16:540-3.
91. Rhoden EL, Teloken C, Ting HY, Lucas ML, Teodosio da Ros C, Ary Vargas Souto C. Prevalence of Peyronie's disease in men over 50-year-old from Southern Brazil. Int J Impot Res 2001;13:291-3.
92. Burchardt T, Burchardt M, Karden J, Buttyan R, Shabsigh A, de la Taille A, Ng PY, Anastasiadis AG, Shabsigh R. Reduction of endothelial and smooth muscle density in the corpora cavernosa of the streptozotocin induced diabetic rat. J Urol 2000;164:1807-11.
93. Jevtich MJ, Khawand NY, Vidic B. Clinical significance of ultrastructural findings in the corpora cavernosa of normal and impotent men. J Urol 1990;143:289-93.
94. Fakjian N, Hunter S, Cole GW, Miller J. An argument for circumcision. Prevention of balanitis in the adult. Arch Dermatol 1990;126:1046-7.
95. Drivsholm T, de Fine Olivarius N, Nielsen AB, Siersma V. Symptoms, signs and complications in newly diagnosed type 2 diabetic patients, and their relationship to glycaemia, blood pressure and weight. Diabetologia 2005;48:210-4.
96. Bromage SJ, Crump A, Pearce I. Phimosis as a presenting feature of diabetes. BJU Int 2008;101:338-40.
97. Leiblum SR, ed. Principles and practice of sex therapy. 4th edition. New York, London: The Guilford Press; 2007.
98. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, Carson C 3rd, Cheitlin M, Debusk R, Fonseca V, Ganz P, Goldstein I, Guay A, Hatzichristou D, Hollander JE, Hutter A, Katz S, Kloner RA, Mittleman M, Montorsi F, Montorsi P, Nehra A, Sadovsky R, Shabsigh R. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:313-21.
99. Jackson G. Sexual dysfunction and diabetes. Int J Clin Pract 2004;58:358-62.
100. Fonseca V, Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: Common pathways and treatments? Am J Cardiol 2005;96:13M-18M.
101. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-12.
102. Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, Zinman B, Jacobson A, Sun W, Lachin JM, Nathan DM. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006;55:3556-65.
103. Yaman O, Akand M, Gursoy A, Erdogan MF, Anafarta K. The effect of diabetes mellitus treatment and good glycemic control on the erectile function in men with diabetes mellitus-induced erectile dysfunction: A pilot study. J Sex Med 2006;3:344-8.
104. Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Caselli A, Caballero AE, Economides PA, Veves A, Horton ES. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003;26:2119-25.
105. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, Argaya Roca M, Pol Bravo C, Sanchez Zamorano MA, Ferrario CM. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001;321:336-41.
106. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: A crossover study. Am J Hypertens 2001;14:27-31.
107. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83:3C-12C.
108. Ng KK, Lim HC, Ng FC, Li MK, Consigliere D, Chia SJ, Moorthy P, Munisamy M. The use of sildenafil in patients with erectile dysfunction in relation to diabetes mellitus-a study of 1,511 patients. Singapore Med J 2002;43:387-90.
109. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol 2003;92:19M-25M.
110. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
111. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-6.
112. Saenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-64.
113. Jackson G, Betteridge J, Dean J, Eardley I, Hall R, Holdright D, Holmes S, Kirby M, Riley A, Sever P. A systematic approach to erectile dysfunction in the cardiovascular patient: A consensus statement-update 2002. Int J Clin Pract 2002;56:663-71.
114. Gruenwald I, Shenfeld O, Chen J, Raviv G, Richter S, Cohen A, Vardi Y. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006;50:134-40.
115. Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy for "non-responders" to tadalafil and vardenafil: A real-life study. Eur Urol 2006;50:126-32. Discussion 32-3.
116. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001;22:793-7.
117. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-63.
118. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004;1:292-300.
119. Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P, Auerbach S, Murdock M, Wilkins HJ, McBride TA, Colopy MW. Erectile response with vardenafil in sildenafil nonresponders: A multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004;94:1301-9.
120. Eardley I. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: Converting "non-responders"into "responders". Eur Urol 2006;50:31-3.
121. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336:1-7.
122. Urciuoli R, Cantisani TA, Carlinil M, Giuglietti M, Botti FM. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev 2004;2:CD001784. DOI:10.1002/14651858.CD001784.pub2
123. Shabsigh R, Padma-Nathan H, Gittleman M, McMurray J, Kaufman J, Goldstein I. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: A comparative, randomized, crossover, multicenter study. Urology 2000;55:109-13.
124. Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Diabetic impotence treated by intracavernosal injections: High treatment compliance and increasing dosage of vaso-active drugs. Eur Urol 2001;40:398-402. Discussion 03.
125. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334:873-7.
126. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 2005;48:1-4.
127. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: Results of a meta-analysis. J Urol 2000;164:371-5.
128. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632-8.
129. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-9.
130. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
131. Israilov S, Shmuely J, Niv E, Engelstein D, Livne P, Boniel J. Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2005;17:431-6.
132. Wilson SK, Carson CC, Cleves MA, Delk JR 2nd. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol 1998;159:1537-9. Discussion 39-40.
133. Bishop JR, Moul JW, Sihelnik SA, Peppas DS, Gormley TS, McLeod DG. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol 1992;147:386-8.